Reviewer’s report

Title: PAMs Inhibits Monoamine Oxidase A Activity and Reduces Glioma Tumor Growth, a Potential Adjuvant Treatment for Glioma

Version: 0 Date: 23 Mar 2020

Reviewer's report:

Study is of topical interest.
1. It's good that PAMs showed promising anti-cancer prospects. The phytochemical and/or microbial characterizations of PAMs are necessary to enrich findings. As it is, findings are preliminary as there is no information on likely constituents of PAMs.
2. Toxicity in normal cell lines necessary to aid estimation of therapeutic window. Toxicity towards the cancer cell lines could have been general.
3. Combination treatment effect was determined at single dose. Could authors justify this?
   In combination treatments, authors pre-treated with TMZ for 48 h before incubating with PAMs. Why? Treatments could have been simultaneous.
4. For the MAO A inhibition assay, inclusion of a reference inhibitor would have been appropriate to validate assay. For example, CLORGYLINE, a known inhibitor of MAO could have been included to benchmark.
5. Why did authors include CLORGYLINE for in vivo experiments only?

Are the methods appropriate and well described?
If not, please specify what is required in your comments to the authors.

Yes

Does the work include the necessary controls?
If not, please specify which controls are required in your comments to the authors.

No

Are the conclusions drawn adequately supported by the data shown?
If not, please explain in your comments to the authors.

Yes

Are you able to assess any statistics in the manuscript or would you recommend an additional statistical review?
If an additional statistical review is recommended, please specify what aspects require further assessment in your comments to the editors.

I am able to assess the statistics
Quality of written English
Please indicate the quality of language in the manuscript:

Needs some language corrections before being published

Declaration of competing interests
Please complete a declaration of competing interests, considering the following questions:

1. Have you in the past five years received reimbursements, fees, funding, or salary from an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

2. Do you hold any stocks or shares in an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

3. Do you hold or are you currently applying for any patents relating to the content of the manuscript?

4. Have you received reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript?

5. Do you have any other financial competing interests?

6. Do you have any non-financial competing interests in relation to this paper?

If you can answer no to all of the above, write 'I declare that I have no competing interests' below. If your reply is yes to any, please give details below.

I declare that I have no competing interests

I agree to the open peer review policy of the journal. I understand that my name will be included on my report to the authors and, if the manuscript is accepted for publication, my named report including any attachments I upload will be posted on the website along with the authors' responses. I agree for my report to be made available under an Open Access Creative Commons CC-BY license (http://creativecommons.org/licenses/by/4.0/). I understand that any comments which I do not wish to be included in my named report can be included as confidential comments to the editors, which will not be published.

I agree to the open peer review policy of the journal